The European Commission said Wednesday that it had given formal approval for Leqembi, a long-awaited new treatment for ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

The natural gas market continues to hang around the crucial 200 Day EMA on Wednesday, as we are trying to price in the idea of a rollover into warmer temperatures in the United States and Europe. With ...

Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi ...

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sandoz is alleging Amgen's patent actions were anticompetitive.

Neurizon Therapeutics (ASX:NUZ) has appointed three new executives as it focuses on lifting the clinical hold for NUZ-001’s ...